Liver MRI could spot dangerous drug interactions early
NCT ID NCT07541807
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether a special MRI scan can measure how two common drugs, metformin and ciclosporin, affect the liver. Twelve healthy volunteers received the MRI dye gadoxetate before and after taking the drugs. The goal was to see if the scan could detect changes in liver function, which could help identify risky drug interactions earlier in development.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gadoxetate (MRI dye), metformin, ciclosporin
- What this could lead to
- If successful, this could lead to a safer, non-invasive way to test how new drugs interact with the liver, reducing drug development failures.
- What could go wrong
- This is a very small, early-phase study in healthy volunteers, not patients. The MRI method may not prove reliable enough for widespread use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Hallamshire Hospital
Sheffield, United Kingdom
-
University of Sheffield, POLARIS, 18 Claremont Crescent
Sheffield, S10 2RX, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.